Seagen Inc. which can be found using ticker (SGEN) have now 11 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The target price High/Low ranges between $229.00 and $228.00 calculating the mean target price we have $228.91. Given that the stocks previous close was at $211.85 this indicates there is a potential upside of 8.1%. There is a 50 day moving average of $213.12 while the 200 day moving average is $197.67. The market capitalization for the company is 40.41B. The current share price for the company is: $214.17 USD
The potential market cap would be $43,659,792,581 based on the market consensus.
The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of $12.29 and a -12.94% return on assets.
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
